当前位置: X-MOL 学术Clin. Neuroradiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Aggregometry Response to Half-dose Prasugrel in Flow-diverting Stent Implantation.
Clinical Neuroradiology ( IF 2.4 ) Pub Date : 2019-06-04 , DOI: 10.1007/s00062-019-00804-1
Ismail Oran 1 , Celal Cinar 1 , Mustafa Gok 2 , Fatih Duzgun 3
Affiliation  

Purpose

The aim of this study was to determine whether half-dose loading (30 mg) of prasugrel is sufficient to achieve adequate platelet inhibition, and whether such a loading dose of prasugrel together with aspirin followed by a 10 mg/day prasugrel maintenance, could serve as a first-line antiplatelet strategy for patients undergoing flow-diverting stent (FDS) implantation.

Methods

Data from a group of consecutive patients treated for intracranial aneurysm with FDS were retrospectively collected. Platelet P2Y12 receptor responsiveness was assessed by a rapid platelet function test just prior to the procedure. All ischemic and hemorrhagic complications as well as morbidity and mortality rates were documented.

Results

A total of 138 patients with 153 aneurysms (32 were symptomatic and 121 were incidental) underwent FDS treatment in a total of 147 loading sessions. Adequate platelet inhibition was obtained in 136/138 (98.5%) patients and 145/147 (98.6%) loading sessions. Overall, there was one case of (hemorrhagic) mortality (0.7%), one of (ischemic) morbidity (0.7%), one of symptomatic (hemorrhagic) clinical complications without permanent deficits (0.7%), and six transient ischemic attacks (4.1%). The 6‑month control angiography, available for all patients, revealed a 95.4% aneurysm occlusion rate.

Conclusion

Half-dose (30 mg) prasugrel loading results in effective platelet P2Y12 receptor inhibition in more than 98% of patients. Dual antiaggregant loading with half dose prasugrel followed by prasugrel maintenance as a first-line therapy appears to be feasible in patients treated with FDS implantation for intracranial aneurysm.


中文翻译:

在分流支架植入中对半剂量普拉格雷的凝集反应。

目的

这项研究的目的是确定普拉格雷的半剂量负荷量(30 mg)是否足以实现足够的血小板抑制作用,普拉格雷与阿司匹林并用10毫克/天的普拉格雷维持剂量是否能有效作为接受分流支架(FDS)植入的患者的一线抗血小板策略。

方法

回顾性收集了一组接受FDS治疗颅内动脉瘤的连续患者的数据。在手术前立即通过快速血小板功能测试评估血小板P2Y12受体反应性。记录所有缺血性和出血性并发症以及发病率和死亡率。

结果

总共147次负荷治疗,总共138例动脉瘤153例(有症状的32例,偶发的121例)接受了FDS治疗。136/138(98.5%)患者和145/147(98.6%)负荷患者获得了足够的血小板抑制。总体而言,一例(出血性)死亡率(0.7%),一例(缺血性)发病率(0.7%),一例无永久性缺陷的有症状(出血性)临床并发症(0.7%)和六例短暂性脑缺血发作(4.1) %)。所有患者均可进行为期6个月的对照血管造影,显示95.4%的动脉瘤闭塞率。

结论

半剂量(30 mg)普拉格雷剂量可在98%以上的患者中有效抑制血小板P2Y12受体。对于颅内动脉瘤行FDS植入的患者,以半剂量普拉格雷进行双重抗凝集治疗,然后采用普拉格雷维持作为一线治疗似乎是可行的。
更新日期:2019-06-04
down
wechat
bug